Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ZM

Zoom Communications Inc

Feb 12 • 12:17PM ET

89.99

-2.16 -2.35 %

Technology • Software - Application • USA • NASD

Peers: MSFT GOOG GOOGL CRM CSCO ADBE RNG TEAM FIVN LOGI

| Held by: VTI VO VXF VGT VTV VFLO VOE COWZ IWR IGV

Index	-	P/E	17.48	EPS (ttm)	5.15	Insider Own	10.61%	Shs Outstand	266.35M	Perf Week	1.02%
Market Cap	26.64B	Forward P/E	14.83	EPS next Y	6.07	Insider Trans	-2.51%	Shs Float	264.69M	Perf Month	8.17%
Enterprise Value	18.74B	PEG	3.27	EPS next Q	1.49	Inst Own	68.83%	Short Float	2.42%	Perf Quarter	6.38%
Income	1.59B	P/S	5.54	EPS this Y	7.74%	Inst Trans	3.69%	Short Ratio	1.93	Perf Half Y	24.31%
Sales	4.81B	P/B	2.88	EPS next Y	1.64%	ROA	14.44%	Short Interest	6.40M	Perf YTD	4.28%
Book/sh	31.27	P/C	3.35	EPS next 5Y	4.54%	ROE	17.74%	52W High	97.58 -7.78%	Perf Year	8.35%
Cash/sh	26.87	P/FCF	13.31	EPS past 3/5Y	-10.66% 106.45%	ROIC	17.11%	52W Low	64.41 39.71%	Perf 3Y	21.26%
Dividend Est.	-	EV/EBITDA	14.37	Sales past 3/5Y	4.40% 49.60%	Gross Margin	76.89%	Volatility	5.15% 4.41%	Perf 5Y	-79.22%
Dividend TTM	-	EV/Sales	3.90	EPS Y/Y TTM	72.42%	Oper. Margin	22.86%	ATR (14)	3.86	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.36	Sales Y/Y TTM	3.85%	Profit Margin	33.17%	RSI (14)	50.52	Recom	2.12
Dividend Gr. 3/5Y	- -	Current Ratio	4.36	EPS Q/Q	204.90%	SMA20	0.41%	Beta	0.90	Target Price	97.69
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	4.44%	SMA50	2.22%	Rel Volume	0.94	Prev Close	92.15
Employees	7412	LT Debt/Eq	0.00	Earnings	Feb 25 AMC	SMA200	9.98%	Avg Volume	3.31M	Price	89.99
IPO	Apr 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.65% 1.25%	Trades		Volume	1,423,992	Change	-2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-05-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$115
Jan-12-26	Upgrade	Citigroup	Neutral → Buy	$106
Dec-17-25	Resumed	BTIG Research	Buy	$105
Oct-21-25	Resumed	Morgan Stanley	Equal-Weight	$85
Oct-20-25	Resumed	UBS	Neutral	$85
Jun-06-25	Initiated	KeyBanc Capital Markets	Underweight
May-22-25	Upgrade	Needham	Hold → Buy	$100
Jan-17-25	Initiated	Cantor Fitzgerald	Neutral	$87
Jan-07-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$70 → $85
Dec-19-24	Upgrade	Jefferies	Hold → Buy	$85 → $100
Nov-26-24	Upgrade	Evercore ISI	In-line → Outperform	$70 → $115
Oct-17-24	Resumed	Wedbush	Outperform	$80 → $85
Apr-18-24	Upgrade	Rosenblatt	Neutral → Buy	$75
Mar-19-24	Initiated	Jefferies	Hold	$70
Jan-18-24	Downgrade	Exane BNP Paribas	Neutral → Underperform	$60
Dec-20-23	Downgrade	Wells Fargo	Equal Weight → Underweight	$70
Nov-17-23	Upgrade	Citigroup	Sell → Neutral	$66
Sep-15-23	Initiated	HSBC Securities	Buy	$83
May-23-23	Upgrade	MoffettNathanson	Underperform → Market Perform	$85
Mar-24-23	Initiated	Rosenblatt	Neutral	$75

Show Previous Ratings

Feb-11-26 11:40PM	3 Overrated Stocks We Steer Clear Of (StockStory)
05:45PM	Zoom Communications (ZM) Dips More Than Broader Market: What You Should Know (Zacks)
09:00AM	Zoom Communications, Inc. (ZM) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-10-26 11:40AM	APPS or ZM: Which Is the Better Value Stock Right Now? (Zacks)
Feb-09-26 10:31AM	Cango sells $305 million in bitcoin to pay down debt amid AI shift (Blockspace)
11:32PM	Loading…
Feb-08-26 11:32PM	3 Mid-Cap Stocks We Think Twice About (StockStory)
Feb-05-26 11:36PM	3 Profitable Stocks with Warning Signs (StockStory)
10:12AM	Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls (The Fly)
07:58AM	Here Are Thursdays Top Wall Street Analyst Research Calls: CAVA Group, DigitalOcean, Fox Corp, Jack Henry, Microsoft, Qualcomm, Snap, Zoom Communications, and More (24/7 Wall St.)
Feb-04-26 06:15PM	Sangoma Technologies Corporation (SANG) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:45PM	Zoom Communications (ZM) Rises As Market Takes a Dip: Key Facts (Zacks)
Feb-03-26 04:46AM	Top Strategist Says Investors Are Overlooking Europe's 'Kill Switch' For US Tech- What It Means For Zoom, Microsoft, Cisco (Benzinga)
Feb-02-26 10:22AM	Why 1 Analyst Thinks Zoom Stock Is Set to Be an Unexpected AI Winner (Barchart)
Jan-30-26 03:31PM	Zoom (ZM) Investment Pays Off Huge (24/7 Wall St.)
Jan-29-26 05:45PM	Zoom Communications (ZM) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
04:05PM	Loading…
04:05PM	Zoom to Release Financial Results for the Fourth Quarter and Full Fiscal Year 2026 (GlobeNewswire)
Jan-27-26 11:17PM	AI News: Chatbot Wars, Soaring Valuations, & Disruption (Zacks)
02:21PM	Zoom's Anthropic Stake and Huge Cash Pile Could Change the Story (MarketBeat)
10:45AM	Pfizer, Merck, CoreWeave, Zoom: Top Analyst Calls (Yahoo Finance Video)
10:40AM	Cloudflare Stock Pops On Anthropic's Claude AI Tools. Zoom Also Gets Anthropic Boost. (Investor's Business Daily)
06:31AM	Zoom Shares Spike After Calls AI Investment a 'Hidden Gem' (GuruFocus.com)
Jan-26-26 08:18PM	USA Rare Earth, GameStop, CoreWeave, Zoom And UnitedHealth: Why These 5 Stocks Are On Investors' Radars Today (Benzinga) +11.28%
07:31PM	Analyst Report: Zoom Communications, Inc. (Morningstar Research)
07:04PM	Why Zoom Stock Zoomed More Than 11% Higher on Monday (Motley Fool)
03:58PM	What's Driving The Surge In Zoom Stock? (Benzinga)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet)
11:45AM	Zoom Stock Is Soaring. Its Investment in Anthropic Is a 'Hidden Gem.' (Barrons.com)
Jan-23-26 05:45PM	Zoom Communications (ZM) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Jan-22-26 09:01AM	Top Four Tech Stocks Poised for Earnings Breakouts, According to WarrenAI (Investing.com)
09:00AM	Loading…
09:00AM	Zoom Communications, Inc. (ZM) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
05:00AM	Bull of the Day: Zoom Video Communications (ZM) (Zacks)
02:49AM	Zoom Video and Lamb Weston have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Jan-20-26 10:27AM	Guidewire Slips 12% in a Year: How to Approach the Stock Now? (Zacks)
Jan-15-26 10:51PM	Analyst Report: Zoom Communications, Inc. (Morningstar Research)
05:45PM	Zoom Communications (ZM) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-12-26 11:04PM	3 Reasons to Sell ZM and 1 Stock to Buy Instead (StockStory)
07:24PM	Time For This Pandemic Favorite Stock to Roar Back? (Zacks)
01:11PM	Citi Sees Fresh Momentum Building at Zoom (GuruFocus.com)
01:07PM	Zoom Stock Surges After Citi Upgrade on AI Growth Bets (GuruFocus.com)
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
09:57AM	Stocks Retreat on Concerns Over Fed Independence (Barchart)
09:49AM	Netflix initiated, Palantir upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Zoom reinforces commitment to AI literacy with national student learning experience (GlobeNewswire)
Jan-08-26 05:50PM	Zoom Communications (ZM) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
09:00AM	Zoom Opens Nominations for First U.S. Solopreneur 50 List, Recognizing AI-First Solo Business Leaders (GlobeNewswire)
Jan-02-26 05:50PM	Zoom Communications (ZM) Stock Sinks As Market Gains: What You Should Know (Zacks)
Dec-24-25 10:33PM	Winners And Losers Of Q3: Zoom (NASDAQ:ZM) Vs The Rest Of The Video Conferencing Stocks (StockStory)
11:30AM	Zoom (ZM) Up 1% Since Last Earnings Report: Can It Continue? (Zacks)
09:50AM	Why Zoom Communications (ZM) is a Top Momentum Stock for the Long-Term (Zacks)
09:00AM	Zoom Communications, Inc. (ZM) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Dec-23-25 09:45AM	Zoom Communications (ZM) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
Dec-22-25 11:37PM	3 Inflated Stocks with Open Questions (StockStory)
Dec-15-25 11:51PM	Analysts Maintain Neutral Outlook on Zoom (ZM) Following Strong Earnings and Defense Expansion (Insider Monkey)
09:15AM	Zoom Communications, Inc. (ZM) Hits Fresh High: Is There Still Room to Run? (Zacks)
09:00AM	Zoom launches AI Companion 3.0 with agentic workflows, transforming conversations into action (GlobeNewswire)
05:10AM	Zacks Market Edge Highlights: NVIDIA, Newmont, Atlassian, Genpact and Zoom Communications (Zacks)
Dec-12-25 11:59AM	Will There Be a Recession in 2026? (Zacks)
Dec-11-25 11:35PM	1 Mid-Cap Stock for Long-Term Investors and 2 We Find Risky (StockStory)
Dec-10-25 09:00AM	Zoom Communications, Inc. (ZM) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:29AM	Zoom Leads A Workplace Revolution (GlobeNewswire)
Dec-08-25 07:29PM	Analyst Report: Zoom Communications, Inc. (Morningstar Research)
Dec-07-25 11:31PM	2 Cash-Producing Stocks to Target This Week and 1 We Avoid (StockStory)
Dec-06-25 02:00AM	AI Stocks Are a Bet on the Future. Markets Are Ignoring the Now. (Barrons.com)
Dec-05-25 12:20PM	Earnings Estimates Rising for Zoom (ZM): Will It Gain? (Zacks)
12:01PM	Cloudflares Second Outage in 3 Weeks Hits Coinbase, Others. The Stock Barely Budges. (Barrons.com)
08:12AM	Cloudflare's Second Outage in 3 Weeks Hits Coinbase, Others. The Stock Falls. (Barrons.com)
Dec-04-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:23AM	Zoom Communications Inc. (ZM): A Bull Case Theory (Insider Monkey)
Dec-03-25 09:45AM	Here's Why Zoom Communications (ZM) is a Strong Growth Stock (Zacks)
Dec-01-25 12:45PM	3 Reasons Growth Investors Will Love Zoom (ZM) (Zacks)
12:19PM	5 Must-Read Analyst Questions From Zoom's Q3 Earnings Call (StockStory)
Nov-28-25 09:00AM	Investors Heavily Search Zoom Communications, Inc. (ZM): Here is What You Need to Know (Zacks)
Nov-26-25 04:55PM	Earnings live: Zscaler stock tanks, Dell rises, Deere slides in last major earnings day this week (Yahoo Finance)
08:38AM	Zoom Communications (ZM) Hits New Record High After Q3 Blowout, Upbeat Outlook (Insider Monkey)
07:45AM	Earnings live: Dell stock rises, Deere and Zscaler slide in last major earnings day this week (Yahoo Finance)
Nov-25-25 04:56PM	Earnings live: Kohl's stock soars 42% following Q3 earnings, Zscaler falls after hours, Dell rises (Yahoo Finance) +9.85%
04:56PM	Earnings live: Kohl's stock soars 42% after Q3 earnings, Zscaler falls after hours, Dell rises (Yahoo Finance)
01:00PM	Zoom (ZM) Shares Skyrocket, What You Need To Know (StockStory)
11:57AM	Why Zoom Stock Zoomed Today (Motley Fool)
11:44AM	Zoom Q3 Earnings & Revenues Surpass Estimates, Both Increase Y/Y (Zacks)
10:58AM	Stocks to Watch Tuesday: Alibaba, Alphabet, Nio, TSM (The Wall Street Journal)
10:50AM	Symbotic stock surges on Q1 outlook, Sandisk to join S&P 500 (Yahoo Finance Video)
09:42AM	Stocks to Watch Tuesday: Alibaba, Alphabet, Novo Nordisk, Kohl's (The Wall Street Journal)
08:30AM	Zoom Lifts Full-Year Outlook As AI Demand Jumps (GuruFocus.com)
08:15AM	Earnings live: Kohl's, Abercrombie stocks soar on Q3 results, Alibaba rises (Yahoo Finance)
08:04AM	The AI stocks still rising (it's not just GOOGL) (Yahoo Finance Video)
06:12AM	S&P Futures Tick Lower With Focus on U.S. Retail Sales and PPI Data (Barchart)
06:01AM	Zoom shares rise after earnings, and other early market movers (MarketWatch)
12:31AM	ZM Q3 Deep Dive: AI Platform Expansion and Profit Growth Define Quarter (StockStory)
12:01AM	Zoom Communications Inc (ZM) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and AI ... (GuruFocus.com)
Nov-24-25 09:25PM	Analyst Report: Zoom Communications Inc. (Morningstar Research)
06:30PM	Zoom (ZM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:01PM	Revenge of Tech: AI, Crypto Bounce Back (Zacks)
05:20PM	Zoom Communications (ZM) Q3 Earnings and Revenues Surpass Estimates (Zacks)
05:15PM	Stock Market Roars To Key Level As Tesla, Palantir, Broadcom Jump; What To Do Now (Investor's Business Daily)
05:07PM	Zoom Stock Rises After Earnings Beat Estimates, Signs of More AI Adoption (Barrons.com)
04:41PM	Zoom lifts annual outlook on growing demand for AI tools in hybrid work (Reuters)
04:30PM	Zoom (NASDAQ:ZM) Exceeds Q3 CY2025 Expectations (StockStory)
04:30PM	Earnings live: Zoom stock pops after upbeat results as CEO touts AI adoption (Yahoo Finance)

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Subotovsky Santiago	Director	Feb 05 '26	Sale	90.39	2,475	223,716	155,917	Feb 09 05:30 PM
Santiago Subotovsky	Director	Feb 05 '26	Proposed Sale	89.08	4,950	440,946		Feb 05 04:30 PM
Yuan Eric S.	Chief Executive Officer	Feb 02 '26	Sale	93.01	12,100	1,125,412	0	Feb 04 05:28 PM
Yuan Eric S.	Chief Executive Officer	Feb 03 '26	Sale	89.31	12,100	1,080,664	0	Feb 04 05:28 PM
DANIEL SCHEINMAN	Director	Jan 27 '26	Proposed Sale	96.75	20,000	1,935,000		Jan 27 04:01 PM
Bawa Aparna	Chief Operating Officer	Jan 16 '26	Sale	81.37	12,137	987,553	1,978	Jan 21 06:24 PM
Aparna Bawa	Officer	Jan 16 '26	Proposed Sale	81.52	12,137	989,408		Jan 16 04:35 PM
Yuan Eric S.	Chief Executive Officer	Jan 13 '26	Sale	83.65	47,369	3,962,355	0	Jan 15 08:29 PM
Yuan Eric S.	Chief Executive Officer	Jan 14 '26	Sale	83.46	12,100	1,009,834	0	Jan 15 08:29 PM
Chang Michelle	Chief Financial Officer	Jan 09 '26	Option Exercise	0.00	22,217	0	42,756	Jan 13 07:21 PM
Chang Michelle	Chief Financial Officer	Jan 12 '26	Sale	86.54	8,417	728,424	25,482	Jan 13 07:21 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jan 09 '26	Option Exercise	0.00	20,752	0	154,411	Jan 13 07:20 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jan 12 '26	Sale	86.55	7,568	654,997	136,182	Jan 13 07:20 PM
Eric S. Yuan	Other: Chief Executive Officer	Jan 13 '26	Proposed Sale	83.19	107,869	8,973,622		Jan 13 04:31 PM
Bawa Aparna	Chief Operating Officer	Jan 08 '26	Option Exercise	0.00	21,392	0	23,370	Jan 12 07:49 PM
Yuan Eric S.	Chief Executive Officer	Jan 08 '26	Option Exercise	0.00	68,453	0	68,453	Jan 12 07:48 PM
VELCHAMY SANKARLINGAM	Officer	Jan 12 '26	Proposed Sale	86.55	7,568	654,986		Jan 12 04:09 PM
MICHELLE CHANG	Officer	Jan 12 '26	Proposed Sale	86.54	8,417	728,443		Jan 12 04:08 PM
Subotovsky Santiago	Director	Jan 05 '26	Sale	86.01	2,475	212,877	145,219	Jan 07 04:33 PM
Yuan Eric S.	Chief Executive Officer	Dec 16 '25	Sale	87.29	73,378	6,404,947	0	Dec 17 04:02 PM
Yuan Eric S.	Chief Executive Officer	Dec 15 '25	Sale	87.05	73,378	6,387,477	0	Dec 17 04:02 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Dec 09 '25	Option Exercise	0.00	7,030	0	139,825	Dec 11 04:21 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Dec 10 '25	Sale	87.84	2,595	227,945	133,659	Dec 11 04:21 PM
VELCHAMY SANKARLINGAM	Officer	Dec 10 '25	Proposed Sale	87.84	2,595	227,945		Dec 10 04:02 PM
Subotovsky Santiago	Director	Dec 04 '25	Sale	86.05	2,475	212,985	147,694	Dec 08 05:45 PM
Yuan Eric S.	Chief Executive Officer	Nov 17 '25	Sale	82.73	73,378	6,070,484	0	Nov 19 05:19 PM
Yuan Eric S.	Chief Executive Officer	Nov 18 '25	Sale	81.27	73,378	5,963,066	0	Nov 19 05:19 PM
Subotovsky Santiago	Director	Nov 04 '25	Sale	84.15	2,475	208,262	150,169	Nov 06 04:02 PM
Yuan Eric S.	Chief Executive Officer	Nov 03 '25	Sale	86.15	73,378	6,321,427	0	Nov 05 07:35 PM
Yuan Eric S.	Chief Executive Officer	Nov 04 '25	Sale	84.16	73,378	6,175,389	0	Nov 05 07:35 PM
Yuan Eric S.	Chief Executive Officer	Oct 23 '25	Sale	82.85	73,378	6,079,544	0	Oct 24 06:29 PM
Yuan Eric S.	Chief Executive Officer	Oct 22 '25	Sale	82.65	73,383	6,065,344	0	Oct 24 06:29 PM
Eric S. Yuan	Other: Chief Executive Officer	Oct 22 '25	Proposed Sale	82.01	733,785	60,177,708		Oct 22 04:38 PM
Bawa Aparna	Chief Operating Officer	Oct 16 '25	Sale	79.77	10,528	839,860	1,978	Oct 20 07:24 PM
Aparna Bawa	Affiliate	Oct 16 '25	Proposed Sale	79.51	10,528	837,081		Oct 16 04:40 PM
Yuan Eric S.	Chief Executive Officer	Oct 13 '25	Sale	79.76	33,692	2,687,368	0	Oct 15 05:37 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Oct 09 '25	Option Exercise	0.00	20,751	0	150,993	Oct 14 07:06 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Oct 10 '25	Sale	82.00	7,660	628,121	132,795	Oct 14 07:06 PM
Chang Michelle	Chief Financial Officer	Oct 09 '25	Option Exercise	0.00	88,869	0	89,465	Oct 14 07:05 PM
Chang Michelle	Chief Financial Officer	Oct 10 '25	Sale	82.00	33,956	2,784,318	20,539	Oct 14 07:05 PM
Eric S. Yuan	Other: Chief Executive Officer	Oct 13 '25	Proposed Sale	79.17	33,692	2,667,396		Oct 14 09:08 AM
Yuan Eric S.	Chief Executive Officer	Oct 08 '25	Option Exercise	0.00	68,454	0	68,454	Oct 10 07:56 PM
Bawa Aparna	Chief Operating Officer	Oct 08 '25	Option Exercise	0.00	21,392	0	23,370	Oct 10 07:56 PM
MICHELLE CHANG	Officer	Oct 10 '25	Proposed Sale	82.00	33,956	2,784,317		Oct 10 04:03 PM
VELCHAMY SANKARLINGAM	Officer	Oct 10 '25	Proposed Sale	82.00	7,660	628,120		Oct 10 04:03 PM
Subotovsky Santiago	Director	Oct 06 '25	Sale	80.78	2,475	199,929	152,644	Oct 08 07:30 PM
Santiago Subotovsky	Director	Oct 06 '25	Proposed Sale	81.03	9,900	802,197		Oct 06 04:48 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Sep 09 '25	Option Exercise	0.00	7,031	0	136,408	Sep 11 07:19 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Sep 10 '25	Sale	85.09	2,595	220,809	130,242	Sep 11 07:19 PM
VELCHAMY SANKARLINGAM	Officer	Sep 10 '25	Proposed Sale	85.09	2,595	220,809		Sep 10 04:17 PM
Subotovsky Santiago	Director	Sep 05 '25	Sale	83.40	2,475	206,424	155,119	Sep 09 07:44 PM
Subotovsky Santiago	Director	Aug 26 '25	Sale	79.65	2,475	197,142	157,594	Aug 27 08:37 PM
McMaster Herbert Raymond	Director	Aug 25 '25	Sale	83.00	2,000	166,000	7,901	Aug 26 07:33 PM
McMaster Herbert Raymond	Director	Aug 22 '25	Sale	80.00	1,000	80,000	9,901	Aug 26 07:33 PM
Chadwick Jonathan	Director	Jul 15 '25	Sale	74.86	25,000	1,871,442	5,875	Jul 16 07:52 PM
Bawa Aparna	Chief Operating Officer	Jul 14 '25	Sale	74.78	10,528	787,329	1,978	Jul 16 07:51 PM
Yuan Eric S.	Chief Executive Officer	Jul 14 '25	Sale	74.79	33,691	2,519,733	0	Jul 16 07:50 PM
McMaster Herbert Raymond	Director	Jul 14 '25	Sale	75.00	500	37,500	10,901	Jul 16 07:48 PM
JONATHAN CHADWICK	Director	Jul 15 '25	Proposed Sale	74.83	25,000	1,870,750		Jul 15 04:24 PM
Eric S. Yuan	Other: Chief Executive Officer	Jul 14 '25	Proposed Sale	74.83	33,691	2,521,098		Jul 14 05:12 PM
Aparna Bawa	Officer	Jul 14 '25	Proposed Sale	73.40	10,528	772,755		Jul 14 04:07 PM
McMaster Herbert Raymond	Director	Jul 14 '25	Proposed Sale	75.00	3,500	262,500		Jul 14 02:16 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jul 09 '25	Option Exercise	0.00	20,752	0	147,576	Jul 10 08:49 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jul 10 '25	Sale	77.50	7,661	593,728	129,377	Jul 10 08:49 PM
Bawa Aparna	Chief Operating Officer	Jul 08 '25	Option Exercise	0.00	21,392	0	23,370	Jul 10 08:44 PM
Yuan Eric S.	Chief Executive Officer	Jul 08 '25	Option Exercise	0.00	68,453	0	68,453	Jul 10 08:42 PM
VELCHAMY SANKARLINGAM	Officer	Jul 10 '25	Proposed Sale	77.50	7,661	593,728		Jul 10 04:07 PM
Subotovsky Santiago	Director	Jul 02 '25	Sale	77.17	2,475	190,996	157,235	Jul 07 09:11 PM
Santiago Subotovsky	Director	Jul 02 '25	Proposed Sale	77.59	7,425	576,106		Jul 02 04:40 PM
Scheinman Daniel	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	10,330	Jun 16 06:16 PM
Gassner Peter P	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	12,744	Jun 13 09:10 PM
Napolitano Janet	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	7,345	Jun 13 09:06 PM
Napolitano Janet	Director	Jun 13 '25	Sale	76.78	2,617	200,922	4,728	Jun 13 09:06 PM
Subotovsky Santiago	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	159,710	Jun 13 09:02 PM
McMaster Herbert Raymond	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	11,401	Jun 13 08:52 PM
McDermott William R	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	11,515	Jun 13 08:50 PM
Hoots Cindy L	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	10,043	Jun 13 08:48 PM
Chadwick Jonathan	Director	Jun 11 '25	Option Exercise	0.00	4,361	0	5,875	Jun 13 08:45 PM
Fenger Michael J.	Director	Jun 11 '25	Option Exercise	0.00	3,738	0	3,738	Jun 13 08:37 PM
JANET ANN NAPOLITANO	Director	Jun 13 '25	Proposed Sale	77.41	2,617	202,582		Jun 13 04:44 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jun 09 '25	Option Exercise	0.00	7,030	0	132,559	Jun 11 07:44 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Jun 10 '25	Sale	80.26	2,595	208,275	126,393	Jun 11 07:44 PM
VELCHAMY SANKARLINGAM	Officer	Jun 10 '25	Proposed Sale	80.26	2,595	208,275		Jun 10 04:01 PM
Subotovsky Santiago	Director	Jun 03 '25	Sale	80.67	2,475	199,663	155,349	Jun 05 07:28 PM
Subotovsky Santiago	Director	May 05 '25	Sale	78.82	2,475	195,087	157,824	May 07 07:26 PM
Subotovsky Santiago	Director	Apr 24 '25	Sale	75.43	2,475	186,684	160,299	Apr 28 07:56 PM
Chadwick Jonathan	Director	Apr 24 '25	Sale	75.03	12,500	937,926	1,514	Apr 28 07:55 PM
Chadwick Jonathan	Director	Apr 15 '25	Sale	72.57	12,500	907,162	1,514	Apr 17 07:10 PM
Bawa Aparna	Chief Operating Officer	Apr 15 '25	Sale	72.59	16,099	1,168,623	1,978	Apr 17 07:09 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Apr 15 '25	Sale	71.91	11,839	851,342	125,529	Apr 17 07:08 PM
Yuan Eric S.	Chief Executive Officer	Apr 14 '25	Sale	72.18	41,121	2,968,229	0	Apr 16 06:28 PM
Aparna Bawa	Officer	Apr 15 '25	Proposed Sale	71.96	16,099	1,158,484		Apr 15 05:02 PM
JONATHAN CHADWICK	Director	Apr 15 '25	Proposed Sale	71.98	25,000	1,799,500		Apr 15 04:30 PM
VELCHAMY SANKARLINGAM	Officer	Apr 15 '25	Proposed Sale	71.91	11,839	851,342		Apr 15 04:04 PM
Eric S. Yuan	Other: Chief Executive Officer	Apr 14 '25	Proposed Sale	71.98	41,121	2,959,890		Apr 14 04:35 PM
Crehan Shane	Chief Accounting Officer	Apr 09 '25	Option Exercise	0.00	7,339	0	13,308	Apr 11 06:37 PM
Sankarlingam Velchamy	Pres. of Engineering & Product	Apr 09 '25	Option Exercise	0.00	32,072	0	143,117	Apr 11 06:36 PM
Bawa Aparna	Chief Operating Officer	Apr 09 '25	Option Exercise	0.00	11,320	0	23,826	Apr 10 09:41 PM
Bawa Aparna	Chief Operating Officer	Apr 08 '25	Option Exercise	0.00	21,392	0	23,370	Apr 10 09:41 PM
Yuan Eric S.	Chief Executive Officer	Apr 09 '25	Option Exercise	0.00	15,093	0	48,786	Apr 10 09:37 PM

Open in Screener

VIR

Vir Biotechnology Inc

Feb 12 • 12:17PM ET

7.11

-0.31 -4.23 %

Healthcare • Biotechnology • USA • NASD

VIR Vir Biotechnology Inc daily Stock Chart

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN-D SNY NVAX

| Held by: IJR VTI XBI IWM VB VBK SPSM VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	32.38%	Shs Outstand	139.02M	Perf Week	2.69%
Market Cap	988.64M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	-6.43%	Shs Float	94.07M	Perf Month	12.62%
Enterprise Value	580.08M	PEG	-	EPS next Q	-0.49	Inst Own	54.27%	Short Float	13.00%	Perf Quarter	24.45%
Income	-499.65M	P/S	58.64	EPS this Y	12.47%	Inst Trans	-3.23%	Short Ratio	6.74	Perf Half Y	55.49%
Sales	16.86M	P/B	1.24	EPS next Y	13.26%	ROA	-39.69%	Short Interest	12.23M	Perf YTD	17.85%
Book/sh	5.73	P/C	1.94	EPS next 5Y	14.29%	ROE	-49.06%	52W High	10.01 -29.01%	Perf Year	-22.00%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	- -18.74%	ROIC	-56.31%	52W Low	4.16 71.03%	Perf 3Y	-72.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.24% 55.77%	Gross Margin	26.74%	Volatility	6.36% 7.40%	Perf 5Y	-89.81%
Dividend TTM	-	EV/Sales	34.41	EPS Y/Y TTM	7.74%	Oper. Margin	-3081.69%	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.25	Sales Y/Y TTM	-78.55%	Profit Margin	-2963.54%	RSI (14)	51.24	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	7.25	EPS Q/Q	24.91%	SMA20	-1.58%	Beta	1.69	Target Price	16.33
Payout	-	Debt/Eq	0.13	Sales Q/Q	-89.92%	SMA50	7.54%	Rel Volume	0.35	Prev Close	7.42
Employees	408	LT Debt/Eq	0.11	Earnings	Feb 23 AMC	SMA200	25.73%	Avg Volume	1.81M	Price	7.11
IPO	Oct 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-38.64% -87.90%	Trades		Volume	293,269	Change	-4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Evercore ISI	Outperform	$12
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy	$14
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62

Show Previous Ratings

Feb-09-26 04:05PM	Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-12-26 08:00AM	Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones (Business Wire)
Jan-05-26 04:05PM	Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 04:05PM	Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program (Business Wire) -5.25%
04:05PM	Loading…
Nov-19-25 04:05PM	Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-09-25 06:07PM	Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile (Business Wire)
Nov-07-25 09:00AM	Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference (Business Wire)
Nov-06-25 12:04AM	Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -5.19%
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 08:00AM	Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta (Business Wire) -6.04%
Oct-29-25 11:48AM	GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View (Zacks) -8.09%
Oct-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) -5.56%
Oct-09-25 04:05PM	Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer (Business Wire)
09:27AM	Loading…
09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-07-25 08:00AM	Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting 2025 (Business Wire)
Aug-27-25 04:21PM	Vir Stock Soars After BofA Boosts Rating on Liver Therapy (GuruFocus.com) +17.79%
09:34AM	Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-25-25 04:05PM	Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.37%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results (Business Wire)
08:05AM	Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-31-25 08:05AM	Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-30-25 11:42AM	GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise (Zacks)
10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-25-25 05:50AM	First subject dosed in Phase I trial of Vir Biotechnologys VIR-5525 (Clinical Trials Arena)
Jul-24-25 08:05AM	Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors (Business Wire)
Jul-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire)
Jul-14-25 09:52AM	Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board (Business Wire)
09:40AM	Loading…
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
May-28-25 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.03%
May-20-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit (Business Wire)
May-12-25 04:05PM	Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference (Business Wire) -11.32%
May-09-25 06:00AM	Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study (Business Wire) -6.01%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 11:21PM	Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus (Seeking Alpha)
11:21PM	Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
Apr-24-25 09:30AM	Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 (Business Wire) +5.36%
Apr-09-25 09:43AM	Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple (Insider Monkey) +10.21%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Feb 02 '26	Sale	7.71	22,000	169,671	1,144,391	Feb 03 12:28 PM
SVF Endurance (Cayman) Limited	Stockholder	Jan 14 '26	Proposed Sale	6.82	1,251,303	8,533,886		Jan 14 09:00 PM
SATO VICKI L	Director	Jan 02 '26	Sale	5.93	22,000	130,383	1,166,391	Jan 05 01:57 PM
VICKI LEE SATO	Director	Jan 02 '26	Proposed Sale	6.03	66,000	397,980		Jan 02 04:29 PM
SVF Endurance (Cayman) Ltd	10% Owner	Dec 01 '25	Sale	5.98	191,854	1,147,786	13,728,924	Dec 03 04:30 PM
SATO VICKI L	Director	Dec 01 '25	Sale	6.00	22,000	132,070	1,188,391	Dec 02 07:48 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 26 '25	Sale	6.39	127,938	817,652	13,982,271	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 28 '25	Sale	6.44	61,493	396,015	13,920,778	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 25 '25	Sale	6.38	235,971	1,505,495	14,110,209	Nov 26 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 24 '25	Sale	6.15	227,803	1,400,783	14,346,180	Nov 26 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Nov 25 '25	Proposed Sale	6.44	1,251,303	8,058,391		Nov 25 09:00 PM
O'Byrne Jason	EVP & Chief Financial Officer	Nov 17 '25	Sale	5.56	6,799	37,782	110,701	Nov 18 02:47 PM
O'Byrne Jason	Officer	Nov 17 '25	Proposed Sale	5.56	6,799	37,781		Nov 17 03:20 PM
de Verneuil Vanina	EVP, General Counsel, Corp Sec	Nov 05 '25	Sale	5.16	2,385	12,307	78,210	Nov 07 03:27 PM
de Verneuil Vanina	Officer	Nov 05 '25	Proposed Sale	5.16	2,385	12,307		Nov 05 09:47 AM
de Verneuil Vanina	EVP and General Counsel	Nov 03 '25	Sale	5.86	1,365	8,003	80,595	Nov 04 07:40 PM
SATO VICKI L	Director	Nov 03 '25	Sale	5.64	22,000	124,047	1,210,391	Nov 04 11:58 AM
de Verneuil Vanina	Officer	Nov 03 '25	Proposed Sale	5.86	1,365	8,003		Nov 03 03:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 28 '25	Sale	6.50	24,453	159,006	14,574,083	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 29 '25	Sale	6.49	100	649	14,573,983	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 27 '25	Sale	6.05	66,403	401,585	14,598,536	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 24 '25	Sale	5.96	46,696	278,285	14,664,939	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 23 '25	Sale	5.99	154,383	924,723	14,711,635	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 22 '25	Sale	6.15	144,266	887,654	14,866,018	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 20 '25	Sale	6.20	220,535	1,367,273	15,119,959	Oct 22 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 21 '25	Sale	6.30	109,675	690,974	15,010,284	Oct 22 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 21 '25	Proposed Sale	6.27	834,202	5,230,447		Oct 21 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 15 '25	Sale	6.07	16,671	101,196	15,353,338	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 16 '25	Sale	6.10	12,844	78,366	15,340,494	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 09 '25	Sale	6.14	249,060	1,529,926	15,372,309	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 10 '25	Sale	6.08	2,300	13,973	15,370,009	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 08 '25	Sale	6.05	466,242	2,819,785	15,621,369	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 07 '25	Sale	5.60	72,133	404,154	16,087,611	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 03 '25	Sale	5.56	450,342	2,501,785	16,233,699	Oct 07 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 06 '25	Sale	5.69	73,955	420,641	16,159,744	Oct 07 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 03 '25	Proposed Sale	5.71	1,668,404	9,526,587		Oct 03 05:00 PM
SATO VICKI L	Director	Oct 01 '25	Sale	5.84	22,000	128,396	1,232,391	Oct 02 11:53 AM
VICKI LEE SATO	Director	Oct 01 '25	Proposed Sale	5.71	66,000	376,860		Oct 01 04:32 PM
SATO VICKI L	Director	Sep 02 '25	Sale	4.99	22,000	109,811	1,254,391	Sep 03 01:50 PM
SATO VICKI L	Director	Aug 01 '25	Sale	4.99	22,000	109,699	1,276,391	Aug 04 12:27 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 15 '25	Sale	5.47	6,796	37,162	108,204	Jul 17 06:46 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 17 '25	Sale	5.47	3,586	19,629	104,618	Jul 17 06:46 PM
MARK EISNER	Officer	Jul 17 '25	Proposed Sale	5.41	3,586	19,400		Jul 17 04:18 PM
Mark Eisner	Officer	Jul 15 '25	Proposed Sale	5.47	6,796	37,162		Jul 15 08:11 PM
SATO VICKI L	Director	Jul 01 '25	Sale	5.10	22,000	112,207	1,298,391	Jul 02 05:03 PM
VICKI LEE SATO	Director	Jul 01 '25	Proposed Sale	5.04	66,000	332,640		Jul 01 04:25 PM
GEORGE SCANGOS	Former Director	Jun 11 '25	Proposed Sale	5.41	19,957	108,037		Jun 11 05:59 PM
GEORGE SCANGOS	Former Director	Jun 10 '25	Proposed Sale	5.48	50,000	273,885		Jun 10 05:04 PM
GEORGE SCANGOS	Former Director	Jun 09 '25	Proposed Sale	5.41	50,000	270,590		Jun 09 05:55 PM
Napolitano Janet	Director	Jun 02 '25	Sale	5.05	3,200	16,149	16,416	Jun 02 07:26 PM
JANET ANN NAPOLITANO	Director	Jun 02 '25	Proposed Sale	4.94	3,200	15,808		Jun 02 04:29 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '25	Sale	5.95	79,712	474,239	769,505	Apr 04 04:23 PM
Marianne De Backer	Officer and Director	Apr 03 '25	Proposed Sale	5.95	79,712	474,239		Apr 03 07:50 PM
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM
SCANGOS GEORGE A	Director	Feb 24 '25	Sale	9.45	10,056	95,063	698,239	Feb 25 03:44 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 24 '25	Sale	9.45	14,168	133,936	117,901	Feb 25 03:43 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 24 '25	Sale	9.45	1,562	14,766	46,627	Feb 25 03:37 PM
De Backer Marianne	Chief Executive Officer	Feb 24 '25	Sale	9.45	16,122	152,408	849,217	Feb 25 03:36 PM
de Verneuil Vanina	EVP and General Counsel	Feb 24 '25	Sale	9.45	5,140	48,590	86,833	Feb 25 03:34 PM
George Scangos	Director	Feb 24 '25	Proposed Sale	9.45	10,056	95,063		Feb 24 08:57 PM
Brent Sabatini	Officer	Feb 24 '25	Proposed Sale	9.45	1,562	14,766		Feb 24 08:57 PM
Ann Hanly	Officer	Feb 24 '25	Proposed Sale	9.45	14,168	133,936		Feb 24 08:56 PM
Vanina de Verneuil	Officer	Feb 24 '25	Proposed Sale	9.45	5,140	48,590		Feb 24 08:40 PM
Marianne De Backer	Officer and Director	Feb 24 '25	Proposed Sale	9.45	16,122	152,408		Feb 24 08:38 PM
SCANGOS GEORGE A	Director	Feb 18 '25	Sale	9.81	10,964	107,575	708,295	Feb 19 07:11 PM
George Scangos	Director	Feb 18 '25	Proposed Sale	9.81	10,964	107,575		Feb 18 07:50 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 13 '25	Sale	9.15	1,562	14,291	28,189	Feb 14 06:41 PM
Brent Sabatini	Officer	Feb 13 '25	Proposed Sale	9.15	1,562	14,291		Feb 13 06:49 PM

ZM

Zoom Communications Inc

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience